NIMG-72. PROGNOSTIC VALUE OF [(18)F]-FDG POSITRON EMISSION TOMOGRAPHY IN PATIENTS WITH RECURRENT GLIOBLASTOMA RECEIVING BEVACIZUMAB

BACKGROUND: Bevacizumab is used extensively for the treatment of recurrent glioblastoma, and its modification of contrast-enhanced MRI creates a need for alternate prognostic read-outs. We sought to determine the prognostic value of [(18)F]-FDG (FDG) PET in glioblastoma patients performed during tre...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neuro Oncol
Asıl Yazarlar: Graham, Maya, Krebs, Simone, Bale, Tejus, Domfe, Kwaku, Lobaugh, Stephanie, Zhang, Zhigang, Dunphy, Mark, Kaley, Thomas, Young, Robert
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2019
Konular:
Neuro-Imaging
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847214/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.741
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller